Transfer Pricing Basics for Life Sciences: Intercompany R&D, IP, and Cost Sharing Overview
Transfer pricing applies to multinational life sciences companies and covers cross-border transfers of goods, services, IP, patents, and trademarks, as well as R&D and manufacturing.
As one of the most significant tax risks a life sciences company will face, meticulous documentation is essential, and pricing strategies must align with market conditions to ensure compliance.
However, we must bear in mind that transfer pricing is not just a compliance issue. Ideally, it should be treated as a component of tax risk management. Understanding the basics of transfer pricing is crucial to avoid unnecessary scrutiny for tax avoidance and the inevitable penalties and adjustments that will follow.
Today, we’ll outline a few transfer pricing considerations, focusing mainly on R&D collaborations, IP ownership and licensing, and cost-sharing structures between subsidiaries.
What Makes Transfer Pricing Unique for Life Sciences Companies?
Life sciences organizations are unique in that they are heavily invested in research and development, with no guaranteed outcome for the products and services in development, and potentially successful products with high long-term returns.
The misalignment between cost and income makes it challenging to allocate costs and profits across jurisdictional boundaries.
Adding to the complexity, IP is the primary vehicle for profitability. Transfer pricing hinges on who owns, develops, and benefits financially from the IP. Tax authorities are laser-focused on ensuring those profits align with value creation, particularly in the area of development, enhancement, maintenance, protection, and exploitation (DEMPE). To the latter point, the goal is to ensure that profits from IP are allocated to the entities that create the value, rather than being distributed among the legal owners (which would appear to be a tax avoidance strategy).
Cross-border collaboration is another issue. It is quite common for affiliates of the same organization to share resources and commercialize products in their respective markets. As such, the pricing structure needs to be clear and defensible, or it will expose the company to audit exposure and, potentially, double taxation.
Let’s look at some of the primary considerations.
Intercompany R&D Arrangements (ICAs)
There are two main types of ICA structures: contract R&D and entrepreneurial R&D. In a contract scenario, a company performs the work on behalf of another group or company, usually the owner of the IP. The contractor is paid on a cost-plus basis and assumes minimal risk.
The entrepreneurial model represents an entity that both performs and funds the R&D and assumes all risks. In this case, the company is entitled to a greater share of returns, which may include ownership or equity in the IP.
Here are a few things to think about:
Which entity carries the most risk if the project fails?
Who makes the directional and funding decisions?
Is the compensation aligned with the work performed and the assumed risk level?
The compensation must reflect “arms-length” principles and be supported by appropriate benchmarking to ensure it withstands regulatory scrutiny.
IP Ownership and Licensing
IP includes intangible property such as proprietary technology, patents, clinical data, and knowledge. Viewing IP through a transfer pricing lens asks the entity to distinguish between legal and economic ownership of IP.
Legal ownership refers to who holds the title to the IP. From a tax standpoint, auditors are often more focused on economic ownership, i.e., who controls and performs the DEMPE functions and (therefore) should be entitled to returns.
Intercompany IP arrangements are typically handled through licensing agreements, in which one entity licenses the rights to an affiliate for a specific purpose, such as manufacturing or distribution in certain markets, in exchange for a royalty.
Deciding what that royalty rate should be is where it gets tricky. Factor in the following:
Comparable transactions between unrelated entities
Use profit-based methods if comparisons are limited
Weighing each party’s risks and contributions to the result
If the IP is part of a broader development arrangement, you may need to consider buy-in payments (aka platform contribution transactions), which can add complexity to the calculation.
Cost-sharing arrangements (CSAs)
Life sciences companies often use CSAs to support joint IP development across jurisdictions. Entities participating in a CSA agree to share the project's costs and risks in proportion to what they expect to receive in return.
While CSAs make taxation a little more straightforward, they also introduce compliance issues to consider. Ideally, you’ll want to review cost allocations periodically to ensure they align with outcomes and adjust when needed. You’ll also need to create detailed documentation to support your valuations, assumptions, and the overall structure of the agreement.
Common Transfer Pricing Risks: What to Avoid
Since transfer pricing is an area ripe for audits, it’s critical to avoid common pitfalls to limit exposure. Here are a few to watch for:
Misaligned functions, risks, and returns. For example, if you’ve allocated excessive profits to an entity not involved with R&D decision-making.
Inadequate or incomplete documentation. You must document all transfer pricing decisions to ensure they are defensible.
Inaccurate IP valuation. A common mistake in early-stage or high-growth projects.
Outdated policies. Keep your transfer pricing arrangements up to date and aligned with the most recent data.
Best Practices in Transfer Pricing
Taking a proactive approach to transfer pricing is essential to reduce risk and ensure compliance. The experts at Growise suggest enforcing the following guidelines:
Ensure all legal agreements reflect actual decision-making and activities.
Maintain concurrent pricing reports and analyses to support your decisions.
Review policies regularly as products move through the development cycle.
Align tax, legal, financial, and R&D teams to ensure consistency across disciplines.
Working with a qualified life sciences tax professional can help to keep you focused on the right things so you don’t get sidetracked by unnecessary audits and other complications.
Bottom line? Transfer pricing is a key strategy for growth-stage life sciences companies, requiring clear documentation and proactive planning to mitigate risk, reduce costs, and ensure that tax outcomes align with the reality of your business.
If you have not yet evaluated or revisited your transfer pricing model, working with the life sciences finance experts at Growise could make a meaningful difference.
Set up a call today, and let’s work it out.